Process and compositions for the recovery of ascorbic acid
    91.
    发明授权
    Process and compositions for the recovery of ascorbic acid 失效
    用于回收抗坏血酸的方法和组合物

    公开(公告)号:US6037480A

    公开(公告)日:2000-03-14

    申请号:US952491

    申请日:1998-02-23

    IPC分类号: C07D307/62 C12P17/04

    CPC分类号: C12P17/04 C07D307/62

    摘要: The invention provides an extraction process for the recovery of ascorbic id from an aqueous feed solution containing the acid at a concentration of less than 0.7 mol/kg.

    摘要翻译: PCT No.PCT / US96 / 08093 Sec。 371日期1998年2月23日 102(e)1998年2月23日PCT PCT 1996年5月31日PCT公布。 WO96 / 38433 PCT出版物 日期1996年12月5日本发明提供了从含有浓度小于0.7mol / kg的酸的含水进料溶液中回收抗坏血酸的提取方法。

    One-step synthesis of vitamin-C (L-ascorbic acid)
    92.
    发明授权
    One-step synthesis of vitamin-C (L-ascorbic acid) 失效
    一维合成维生素C(L-抗坏血酸)

    公开(公告)号:US5998634A

    公开(公告)日:1999-12-07

    申请号:US270194

    申请日:1999-03-15

    IPC分类号: C07D307/62

    CPC分类号: C07D307/62

    摘要: A method is provided for producing L-ascorbic acid (Vitamin-C) in a single process step. Starting material, particularly a mixture of compounds from the group consisting of glucose, sorbitol, sorbose, and 2-keto-L-gulonic acid, is catalytically oxidized in aqueous solution by hypochlorous acid. L-ascorbic acid then can be separated from the aqueous solution, and the unconverted reactants recycled for greater conversion. The reaction occurs in the aqueous state at ambient temperature near a pH of 5.5 when an optimum amount of hydrous cobalt-oxide is present in the solution.

    摘要翻译: 提供了在单一工艺步骤中生产L-抗坏血酸(维生素C)的方法。 原料,特别是葡萄糖,山梨糖醇,山梨糖和2-酮-L-古洛糖酸组成的组的混合物在水溶液中被次氯酸催化氧化。 然后可以将L-抗坏血酸与水溶液分离,并且将未转化的反应物再循环以获得更大的转化率。 当溶液中存在最佳量的含水钴氧化物时,反应在环境温度接近pH 5.5的水性状态下发生。

    Production of L-ascorbic acid
    93.
    发明授权
    Production of L-ascorbic acid 失效
    生产L-抗坏血酸

    公开(公告)号:US5902885A

    公开(公告)日:1999-05-11

    申请号:US2513

    申请日:1993-01-08

    IPC分类号: C07D307/62

    CPC分类号: C07D307/62

    摘要: L-ascorbic acid is produced by allowing an acid to act on 2-keto-L-gulonic acid in a mixture solvent of an inert organic solvent and an aliphatic ketone in the presence of water and a surfactant.The method produces L-ascorbic acid in a high yield 90% or more and is an industrially advantageous method.

    摘要翻译: 通过在水和表面活性剂的存在下,在惰性有机溶剂和脂族酮的混合溶剂中使酸作用于2-酮-L-古洛糖酸来制备L-抗坏血酸。 该方法以高产率生产L-抗坏血酸90%以上,是工业上有利的方法。

    Process for making ascorbic acid
    94.
    发明授权
    Process for making ascorbic acid 失效
    制备抗坏血酸的方法

    公开(公告)号:US5702579A

    公开(公告)日:1997-12-30

    申请号:US766695

    申请日:1996-12-13

    申请人: Joachim Veits

    发明人: Joachim Veits

    CPC分类号: C07D307/62

    摘要: A process for the preparation of ascorbic acid starting from an ascorbate is characterized in that an ascorbate, e.g. sodium ascorbate, dissolved in water is decomposed under the influence of an electric field by means of ion-selective membranes into ascorbate ions and cations and the latter are separated spatially from one another and then, as a result of simultaneous generation of protons and hydroxide ions, the ascorbic acid is prepared from the liberated ascorbate ions and protons and, spatially separated therefrom, the corresponding hydroxide, e.g. sodium hydroxide, is also prepared from the cations and hydroxide ions.

    摘要翻译: 从抗坏血酸开始制备抗坏血酸的方法的特征在于抗坏血酸酯,例如抗坏血酸。 溶解在水中的抗坏血酸钠在离子选择性膜的电场作用下分解成抗坏血酸离子和阳离子,后者在空间上彼此分离,然后由于同时产生质子和氢氧根离子 ,抗坏血酸由游离的抗坏血酸离子和质子制备,并与其空间分离相应的氢氧化物,例如 也由阳离子和氢氧根离子制备氢氧化钠。

    Optically pure 4-aryl-2-hydroxytetronic acids
    95.
    发明授权
    Optically pure 4-aryl-2-hydroxytetronic acids 失效
    光学纯的4-芳基-2-羟基十六烷基酸

    公开(公告)号:US5504108A

    公开(公告)日:1996-04-02

    申请号:US350205

    申请日:1994-12-05

    摘要: The present invention relates to a method for synthesis of optically pure stereogenically labile 4-aryl-2-hydroxytetronic acids from an optically pure aidehyde. The invention further relates to the use of such optically pure compounds as potent inhibitors of platelet aggregation by working at the level of cyclooxygenase, and additionally as inhibitors of cyclooxygenase and 5-lipoxygenase. The invention further relates to the pharmaceutical use of such.compounds in the treatment of coronary artery diseases, especially in the treatment and/or prevention of atherosclerosis, and in the treatment of various inflammatory pathologies, especially arthritis.

    摘要翻译: 本发明涉及一种从光学上纯的非离子表面合成光学纯的立体不稳定的4-芳基-2-羟基季戊四醇的方法。 本发明还涉及通过在环氧合酶水平上工作的另外作为环加氧酶和5-脂氧合酶抑制剂的这种光学纯化合物作为有效的血小板聚集抑制剂的用途。 本发明还涉及这种治疗冠状动脉疾病,特别是治疗和/或预防动脉粥样硬化以及治疗各种炎性病理学,特别是关节炎的药物用途。

    Process for preparing ascorbic acid
    97.
    发明授权
    Process for preparing ascorbic acid 失效
    抗坏血酸的制备方法

    公开(公告)号:US5391770A

    公开(公告)日:1995-02-21

    申请号:US171988

    申请日:1993-12-23

    IPC分类号: C07D307/62

    CPC分类号: C07D307/62

    摘要: Process for preparing pure ascorbic acid from 2-keto-L-gulonic acid or its sodium salt, by carrying out the following successive steps:esterification of 2-keto-L-gulonic acid or its sodium saltlactonization to sodium ascorbateoptional separation of the sodium ascorbatedisplacement of the ascorbic acid from its saltseparation of the sodium sulphateseparation and purification of the ascorbic acid from its methanolic or aqueous-methanolic solution.

    摘要翻译: 通过进行以下连续步骤从2-酮-L-古洛糖酸或其钠盐制备纯抗坏血酸的方法:将2-酮-L-古洛糖酸或其钠盐内酯化酯化为抗坏血酸钠任选分离 抗坏血酸钠从硫酸钠的盐分离中分离并从其甲醇或含水甲醇溶液中纯化抗坏血酸。

    Inhibition of bone loss by 4-aryloxy-5-hydroxy-2(5H)-furanones
    98.
    发明授权
    Inhibition of bone loss by 4-aryloxy-5-hydroxy-2(5H)-furanones 失效
    通过4-芳氧基-5-羟基-2(5H) - 呋喃酮抑制骨丢失

    公开(公告)号:US5336687A

    公开(公告)日:1994-08-09

    申请号:US101885

    申请日:1993-08-04

    IPC分类号: C07D307/62 A61K31/34

    CPC分类号: C07D307/62

    摘要: This invention relates to 4-phenoxy (and 4-substituted phenoxy)5-hydroxy-2(5H)-furanones of the formula: ##STR1## where Z is ##STR2## where R is H, halogen, C.sub.1 -C.sub.8 alkyl, C.sub.3 -C.sub.8 cycloalkyl, trifluoromethyl, or ##STR3## and X is H, C.sub.1 -C.sub.8 alkyl, --O--C.sub.1 -C.sub.8 alkyl, or halogen; a process for their preparation, their use in the treatment of osteoporosis, and pharmaceutical compositions thereof.

    摘要翻译: 本发明涉及下式的4-苯氧基(和4-取代的苯氧基)-5-羟基-2(5H) - 呋喃酮:其中Z是烷基,C 3 -C 8环烷基,三氟甲基, 或,X是H,C 1 -C 8烷基,-O-C 1 -C 8烷基或卤素; 其制备方法,其用于治疗骨质疏松症及其药物组合物。

    Optically pure stereogenically labile 4-substituted-2-hydroxytetronic
acids and pharmaceutical use
    99.
    发明授权
    Optically pure stereogenically labile 4-substituted-2-hydroxytetronic acids and pharmaceutical use 失效
    光学纯立体不稳定的4-取代-2-羟基十六烷基酸和药物用途

    公开(公告)号:US5298526A

    公开(公告)日:1994-03-29

    申请号:US847295

    申请日:1992-03-06

    IPC分类号: C07D307/62 A61K31/365

    CPC分类号: C07D307/62

    摘要: The present invention relates to a method for synthesis of optically pure stereogenically labile 4-substituted-2-hydroxytetronic acids from an asymmetric .alpha.-hydroxy ester. The chiron approach of the present invention utilizes a non-nucleophilic lithium amide base under kinetically controlled Claisen conditions to produce a 4-substituted-2-pheylmethoxy precursor to the 4-substituted-2-hydroxy tetronic acid. The invention further relates to the use of such optically pure compounds as potent inhibitors of platelet aggregation by working at the level of cyclooxygenase. The invention further relates to the pharmaceutical use of such compounds in the treatment of coronary artery diseases, especially in the treatment and/or prevention of atherosclerosis.

    摘要翻译: 本发明涉及从不对称(α) - 羟基酯合成光学纯的立体不稳定的4-取代-2-羟基十六烷酸的方法。 本发明的凯龙疗法在动力学控制的Claisen条件下使用非亲核性的氨基化锂碱来制备4-取代-2-羟基四氢酸的4-取代的2-庚基甲氧基前体。 本发明还涉及这种光学纯化合物作为血小板聚集的有效抑制剂在环氧合酶水平上的应用。 本发明进一步涉及这些化合物在治疗冠状动脉疾病中的药物用途,特别是治疗和/或预防动脉粥样硬化。